Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough ... that full-year sales of all its drugs grew 26% to $40.5 billion. However, the company projects that sales growth ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug ... cost alternative to the current injector pen formulation of Zepbound and are easier to produce.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... a 26% growth in revenue for 2024, totaling $40.5 billion. “It’s early days on a very, very large ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45 ... The drugmaker’s stock LLY rose 0.5% in regular trading on ...

Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed $5.64 billion ... Ozempic pre-filled pen and Rybelsus oral ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...